Clinical trials: Chidamide
T-Cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic Lymphoma
Chidamide Maintenance to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute T-Lymphoblastic Leukemia/Lymphoma
This study evaluates whether chidamide maintenance therapy can effectively reduce the risk of relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with high-risk T-cell acute lymphoblastic…
- Trial name
- CHI-HSCT (NCT07774377)
- Testing
- Chidamide, Control Group
- Volunteers
- 132 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Head and Neck Squamous Cell Carcinoma HNSCC
Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy
To evaluate the safety and tolerability of re-irradiation combined with chidamide in patients with recurrent head and neck squamous cell carcinoma after radiotherapy.
- Trial name
- NCT07545967
- Testing
- Chidamide, radiotherapy
- Where
- China
- Volunteers
- 6 people
- Sponsor
- West China Hospital
Cutaneous T-cell Lymphoma (CTCL)
Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma
This is a prospective, single-center phase I/II study, with the purpose of evaluating the efficiency of golidocitinib combined with chidamide in patients with systemically-treated cutaneous T-cell lymphoma.
- Trial name
- NCT07754890
- Testing
- golidocitinib, Chidamide
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Peking Union Medical College Hospital
Advanced Colorectal Cancer in the Third-line Treatment and Beyond, pMMR/MSS Advanced Colorectal Cancer
The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.
Patients with advanced colorectal cancer, particularly those of the pMMR/MSS type, exhibit suboptimal therapeutic responses in the third-line and subsequent treatments.
- Trial name
- NCT06930118
- Testing
- chidamide, regorafenib, and iparomlimab/tuvonralimab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Changzheng Hospital
Diffuse Large B-cell Lymphoma
Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL
Tucidinostat (formerly known as chidamide) is an oral subtype-selective histone deacetylase inhibitor. This Randomized, Double-blind, Placebo-controlled Phase 3 trail is studying the efficacy and safety of Tucidinostat, in…
- Trial name
- DEB (NCT04231448)
- Testing
- R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone), Tucidinostat
- Where
- 2 sites in China
- Volunteers
- 423 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Breast Cancer
Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors
The trial used a multicenter, open, single-arm design in which patients were treated with Chidamide combined with Fulvestrant.The primary objective is to evaluate the preliminary efficacy and safety of Chidamide in combination…
- Trial name
- NCT05191914
- Testing
- Chidamide+ Fulvestrant
- Volunteers
- 20 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Lymphoma, T-Cell, Peripheral
Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
A Randomised, Double-blind, Multicenter Phase Ⅲ Study to Evaluate the Efficacy and Safety of Tucidinostat versus Placebo in Combination with CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma with Follicular Helper of T Cell…
- Trial name
- NCT06947967
- Testing
- CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone), Tucidinostat
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma
This is a single-arm, multicenter phase Ⅱ study to evaluate the therapeutic efficacy and safety of chidamide + sintilimab + bevacizumab in subjects with advanced extrapulmonary neuroendocrine carcinoma who have failed first-line…
- Trial name
- NCT07518602
- Testing
- Chidamide, Sintilimab, Bevacizumab
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Sun Yat-sen University
HIV-1 Infection
A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs
This is a phase II proof-of-concept trial study to assess the safety and efficacy of UB-421 monotherapy plus chidamide in changing the latent HIV reservoir among ART-treated HIV-1 adults with stably viral suppression who undergo…
- Trial name
- NCT05056974
- Testing
- UB-421, chidamide
- Where
- Taiwan
- Volunteers
- 11 people
- Sponsor
- United BioPharma
Angioimmunoblastic T-cell Lymphoma, Chemotherapy Effect
Rituximab Combined With Chidamide and Lenalidomide for r/r AITL
This study is designed to explore the effeicency and toxicities of rituximab combined with chidamide and lenalidomide in patients with relapsed or refractory AITL.
- Conditions
- Angioimmunoblastic T-cell Lymphoma, Chemotherapy Effect, Chemotherapeutic Toxicity
- Trial name
- AITL (NCT04319601)
- Testing
- Rituximab
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Zhejiang Cancer Hospital
Non Hodgkin's Lymphoma
Chidamide Bridging for CAR-T Therapy
The previous research suggests that the low expression of NOXA protein may be an important biomarker for the treatment of drug resistance of chimeric antigen receptor-T (CAR-T) cells.
- Trial name
- NCT05370547
- Testing
- Chidamide, Fludarabine and cyclophosphamide, Anti-CD19 CAR-T cells
- Where
- 13 sites in China
- Volunteers
- 120 people
- Sponsor
- Chinese PLA General Hospital
EBV-Associated Lymphoproliferative Disorders, PD-1 Inhibitor
Application of PD-1 Inhibitors, Tenofovir, Chidamide, and Lenalidomide in Relapsed/Refractory EBV-associated Lymphoproliferative Disorders.
This study is a prospective, multicenter, single-arm clinical trial designed to evaluate the efficacy and safety of PD-1 inhibitor combined with tenofovir, chidamide, and lenalidomide in the treatment of relapsed or refractory…
- Conditions
- EBV-Associated Lymphoproliferative Disorders, PD-1 Inhibitor, Tenofovir, Chidamide
- Trial name
- NCT07133763
- Testing
- PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV-Associated Lymphoproliferative Disorders.
- Volunteers
- 50 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Experimental Tumor
Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients
Chidamide With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide for Peripheral T Cell Lymphoma Patients : a Prospective, Randomized Controlled, Open Label, Phase II Clinical Trial
- Trial name
- NCT03617432
- Testing
- Chidamide, Cyclophosphamide, Doxorubicin
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Peking University
Advanced Microsatellite Stable Colorectal Cancer, Metastatic Microsatellite-stable Colorectal Cancer
Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
The purpose of this study is to evaluate the efficacy and safety of sintilimab and chidamide in combination with or without IBI305(bevacizumab) in patients with standard treatment failure of advanced or metastatic pMMR/MSS…
- Trial name
- NCT04724239
- Testing
- Sintilimab, Chidamide, IBI305
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
HR Positive HER2 Negative Advanced Breast Cancer
A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy
To explore the efficacy and safety of Chidamide combined with endocrine for maintenance therapy after first-line chemotherapy for HR+/HER2- breast cancer
- Trial name
- NCT05890287
- Testing
- Chidamide
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Multiple Myeloma
Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients
In the phase I trial, dose escalation of chidamide will be performed at 4 different dosages (15mg, 20mg, 25mg, 30mg) for optimal dosage, in the phase II trial, the safety and efficacy of chidamide+VRD will be compared with that…
- Trial name
- NCT04025450
- Testing
- Chidamide+VRD, VRD
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
The prognosis for patients with relapsed/refractory classical Hodgkin lymphoma (cHL) who refuse or are ineligible for transplant is poor.
- Trial name
- NCT06563778
- Testing
- Chidamide; Decitabine; Anti-PD-1 Antibody, Brentuximab Vedotin+ Bendamustine+Anti-PD-1 antibody
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
HIV-1-infection
A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral Reservoir
To assess the impact of UB-421 and chidamide in changing HIV-1 viral reservoir profile among HIV-1 suppressed patients who undergo short-term ART interruption.
- Trial name
- NCT04985890
- Testing
- UB-421, UB-421+chidamide
- Volunteers
- 20 people
- Sponsor
- UBP Greater China (Shanghai) Co., Ltd
Angioimmunoblastic T-Cell Lymphoma Recurrent, Angioimmunoblastic T-Cell Lymphoma Refractory
Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL
Angioimmunoblastic T cell lymphoma (AITL) is a rare and aggressive lymphoma. Some patients relapsed after initial treatment or did not respond to standard treatment (refractory).
- Trial name
- NCT07058103
- Testing
- tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Acute Monocytic Leukemia, Newly Diagnosed
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia
This study is to investigate the therapeutic efficacy and side effect of venetoclax, azacytidine combined with chidamide for newly diagnosed acute monocytic leukemia patients that are ineligible for intensive chemotherapy
- Trial name
- NCT05566054
- Testing
- Chidamide, Azacitidine, Venetoclax
- Where
- China
- Volunteers
- 92 people
- Sponsor
- The First Affiliated Hospital of Soochow University